UPPTHERA
UPPTHERA is a biotech company in Incheon, South Korea, founded in 2018.
Synthesize possibilities, degrade despair
- Headquarters
- Incheon
- Employees
- 11–50
- Founded
- 2018
- Business Model
- B2B
- Website
- uppthera.com
About
UPPTHERA is a South Korean pharmaceutical venture company developing innovative cancer therapeutics based on targeted protein degradation (TPD) technology, including PROTACs. The company has built proprietary platforms — UPPGRADER for novel E3 ligase target identification using scRNA-seq analysis, UPPBEAT for covalent ligand screening via chemoproteomics, and SpeedUPP for accelerating hit-to-candidate timelines — enabling it to pursue oncology targets previously considered undruggable. UPPTHERA has entered Phase 1/2a clinical trials with its lead PLK1-targeting degrader for small cell lung cancer and has secured partnerships and investments from firms including YuanBio Venture Capital and Boryung Pharmaceutical.
Summary
It lists 11–50 employees.
Tech & App Stack
1 technology or app tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Similar Companies
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...
Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...
Enveda reads and translates nature’s hidden chemistry to accelerate the discovery of better medic...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/uppthera"><img src="https://indexed.vc/api/badge/company/uppthera" alt="UPPTHERA on Indexed.vc" width="260" height="76" /></a>